secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001326110-26-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio reports 700% YoY revenue growth to $113M; first lung cancer approval in Saudi Arabia
--------------------------------------------------------------------------------

- Full-year 2025 ANKTIVA net product revenue $113M (up ~700% YoY); Q4 net revenue $38.3M (up 431% YoY).
- Unit sales volume increased 750% in 2025 vs 2024; cash and securities $242.8M as of Dec 31, 2025.
- SFDA granted conditional accelerated approval for ANKTIVA + checkpoint inhibitors in metastatic NSCLC (Jan 2026) – first lung cancer approval globally.
- Global regulatory footprint expanded to 33 countries across 4 jurisdictions (US, UK, EU, Saudi Arabia) in under two years.
- Net loss attributable to common stockholders narrowed to $351.4M in 2025 from $413.6M in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/0001326110-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/ibrx-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer